What is the appropriate morning and evening dosing regimen of insulin Mixtard 30/70 (premixed insulin) for a patient currently using Actrapid (regular insulin) 25 U in the morning, 32 U at lunch, and 16 U in the evening?

Converting from Actrapid (Regular Insulin) to Mixtard 30/70 (Premixed Insulin)

For a patient currently on Actrapid 25-32-16 units (total daily dose = 73 units), convert to Mixtard 30/70 by giving approximately 49 units before breakfast and 24 units before dinner, following the 2/3 morning and 1/3 evening distribution recommended by current guidelines.

Conversion Algorithm

Based on the 2025 ADA Standards of Care 111, when converting from a three-times-daily regular insulin regimen to a twice-daily premixed insulin plan:

Step 1: Calculate Total Daily Dose

• Current total: 25 + 32 + 16 = 73 units/day

Step 2: Apply the 2/3 Morning, 1/3 Evening Split

The guidelines specifically recommend for twice-daily premixed insulin 11:

• Morning dose (before breakfast): 2/3 of total = 73 × 0.67 = 49 units
• Evening dose (before dinner): 1/3 of total = 73 × 0.33 = 24 units

Step 3: Initial Dosing Strategy

Start with these calculated doses, but be prepared to adjust based on glucose monitoring:

• Mixtard 30/70: 49 units before breakfast
• Mixtard 30/70: 24 units before dinner

Rationale for This Approach

The conversion from multiple daily injections of regular insulin to premixed insulin follows established principles 11:

• Unit-for-unit conversion: The guidelines state "usually unit per unit at the same total insulin dose, but may require adjustment to individual needs" when converting to premixed regimens
• Distribution pattern: The 2/3 morning and 1/3 evening split is explicitly recommended for twice-daily premixed insulin plans
• Mixtard 30/70 composition: Contains 30% rapid-acting (regular) insulin and 70% intermediate-acting (NPH) insulin, providing both mealtime and basal coverage

Titration and Monitoring

After initiating the new regimen 11:

Increase doses by:

• 1-2 units or 10-15% every 3 days based on glucose patterns

For hypoglycemia:

• Determine the cause
• If no clear reason, lower the corresponding dose by 10-20%

Target glucose monitoring times:

• Fasting (before breakfast) - reflects evening dose adequacy
• Before lunch - reflects morning dose adequacy
• Before dinner - reflects morning dose adequacy
• Bedtime - reflects evening dose adequacy

Important Clinical Considerations

Advantages of Premixed Insulin

Research demonstrates that premixed insulin regimens 2:

• Can achieve HbA1c reductions of 0.6-0.8% when converting from self-mixed regimens
• Improve compliance due to convenience (fewer injections, no mixing required)
• Provide similar glycemic control to self-mixed regimens with ratios ranging from 20/80 to 40/60 3

Common Pitfalls to Avoid

1. Lunch coverage: The patient will lose dedicated lunch-time insulin coverage. The morning Mixtard dose must be sufficient to cover both breakfast and lunch. Monitor pre-dinner glucose closely.

2. Timing is critical: Mixtard 30/70 should be administered 15 minutes before meals 4 due to the regular insulin component requiring time to act.

3. Cannot adjust components separately: Unlike the previous regimen where each meal dose could be adjusted independently, premixed insulin adjusts both rapid and intermediate components together. If glucose control is inadequate at specific times, you may need to revert to a basal-bolus regimen.

4. Risk of hypoglycemia: The intermediate (NPH) component peaks 4-6 hours after injection, so monitor for mid-morning and nighttime hypoglycemia.

When Premixed May Not Be Appropriate

Consider maintaining or switching to a basal-bolus regimen if 11:

• The patient has highly variable meal times or carbohydrate intake
• Significant glucose variability exists between meals
• The patient develops recurrent hypoglycemia with premixed insulin
• HbA1c remains >1.5% above goal despite optimization

Glucagon Prescription

Prescribe glucagon for emergency hypoglycemia management 11 when initiating any insulin regimen, particularly when intensifying therapy.

Expected Outcomes

With appropriate titration, expect 5:

• HbA1c reduction of 1.5-2.5% over 6 months
• Potential weight gain of approximately 3 kg
• Final insulin doses typically 40-70 units/day for adequate control
• Approximately 50% of patients achieve HbA1c ≤7%

The simplified twice-daily regimen should improve adherence while maintaining glycemic control comparable to the previous three-injection regimen 26.